Immunotherapy of kidney cancer

Current Clinical Pharmacology

Volumn 6, Issue 3, 2011, Pages 151-163

  Grivas, Petros D ^a   Redman, Bruce G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cytokine; Immune system; Immunotherapy; Interleukin 2; Kidney cancer; Renal cell carcinoma; Stem cell transplantation; Vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE IX; CD137 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENENICOKIN; GAMMA INTERFERON; GIRENTUXIMAB; GRANZYME B; IPILIMUMAB; MDX 1106; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SUNITINIB; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VITESPEN;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; AUTOIMMUNE THYROIDITIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RESISTANCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CONFUSION; CYTOKINE RELEASE; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DISORIENTATION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENTERITIS; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HORMONE DEFICIENCY; HUMAN; HYPOTENSION; IMMUNOGENICITY; IMMUNOMODULATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER METASTASIS; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MELANOMA; METABOLIC ACIDOSIS; MYALGIA; NATURAL KILLER CELL; NAUSEA; NAUSEA AND VOMITING; NEPHRECTOMY; NONHUMAN; OLIGURIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; REGULATORY T LYMPHOCYTE; RIGOR; SEIZURE; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; TACHYPNEA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WEAKNESS; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; STEM CELL TRANSPLANTATION;

EID: 80052254955     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411797189406     Document Type: Article

References (131)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics CA. Cancer J Clin 2010; 60(5): 277-300.
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353(23): 2477-2490.
3. Yagoda A, Bander NH. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989; 44(6): 338-345.
4. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983; 10(4): 422-430.
5. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006; 24(35): 5576-83.
6. Jenkins MK, Johnson JG. Molecules involved in T-cell costimulation. Curr Opin Immunol 1993; 5: 361-367.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
8. Lotze MT, Grimm EA, Mazumbar A, Strausser JL, Rosenberg SA.Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41(11 Pt1): 4420-4425.
9. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF.Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983; 131(4): 1789-1796.
10. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30(8): 825-830.
11. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37(5): 430-439.
12. Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988; 108(4): 518-523.
13. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85(8): 622-632.
14. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76(5): 824-832.
15. McCabe M, Stablein D, Hawkins MJ. The modified group C experience-phase III randomized trials of IL-2 versus IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 1991; 10: 213.
16. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009; 27(3): 130-139.
17. Su X, Zhang L, Jin L, et al. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm 2010; 25(4): 465-470.
18. Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10(6): 625-632.
19. Wang QJ, Wang H, Pan K, et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 2010; 29(7): 641-648.
20. Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11(3): 341-355.
21. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res 2010; 8(5): 729-738.
22. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009; 113(24): 6120-6127.
23. Ayello J, van de Ven C, Cairo E, et al. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol 2009; 37(10): 1216-1229.
24. Belldegrun A, Tso CL, Sakata T, et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 1993; 85(3): 207-216.
25. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233(4770): 1318-1321.
26. Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. Int J Oncol 2003; 22(2): 431-437.
27. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008; 68(8): 2993-3000.
28. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 1997; 9(5): 702-708.
29. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 2005; 16(7): 799-810.
30. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2(7): 512-519.
31. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumorinfiltrating lymphocytes. J Immunol 2006; 177(9): 6548-6559.
32. Losch FO, Müller R, Mutschler B, et al. Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain. Int J Cancer 2003; 103(3): 399-407.
33. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24(13): e20-22.
34. Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 2000; 96(5): 1999-2001.
35. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005; 174(12): 7853-7858.
36. Willemsen RA, Debets R, Chames P, Bolhuis RL. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003; 64(1): 56-68.
37. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 2009; 74(4): 277-289.
38. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18(4): 666-668.
39. Leisegang M, Turqueti-Neves A, Engels B, et al. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res 2010; 16(8): 2333-2343.
40. Gouttefangeas C, Stenzl A, Stevanovi S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 2007; 56(1): 117-128.
41. Sáenz-López P, Gouttefangeas C, Hennenlotter J, et al. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 2010; 75(2): 110-118.
42. Markel G, Cohen-Sinai T, Besser MJ, et al. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res 2009; 29(1): 145-154.
43. Wölfl M, Kuball J, Eyrich M, Schlegel PG, Greenberg PD. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A 2008; 73(11): 1043-1049.
44. Brosterhus H, Brings S, Leyendeckers H, et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol 1999; 29(12): 4053-4059.
45. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH. Mackall CL4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007; 179(7): 4910-4918.
46. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003; 9(5): 619-624.
47. Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH. IL-12 enhances efficacy and shortens enrichment time in cytokineinduced killer cell immunotherapy. Cancer Immunol Immunother 2010; 59(9): 1325-1334.
48. Diab A, Cohen AD, Alpdogan O, Perales MA. IL-15: targeting CD8+ T cells for immunotherapy. Cytotherapy 2005; 7(1): 23-35.
49. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A. Chemokine receptors expression and migration potential of tumorinfiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 2008; 31(3): 313-323.
50. Sportès C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205(7): 1701-1714.
51. Rosenberg SA, Sportès C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29(3): 313-319.
52. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma Immunol 1984; 132(2): 997-1000.
53. Slavin S, Or R, Prighozina T, et al. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Bone Marrow Transplant 2000; 25(Suppl 2): S54-57.
54. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukemia effect in patient with concurrent breast cancer and acute myelocytic leukemia. Lancet 1996; 348(9036): 1242-1243.
55. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94(9): 2409-2415.
56. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N Engl J Med 2000; 343(11): 750-758.
57. Srinivasan R, Barrett J, Childs R. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol 2004; 31(1): 47-55.
58. Barkholt L, Bregni M, Remberger M, et al. French ITAC group and the EBMT Solid Tumour Working Party. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006; 17(7): 1134-1140.
59. Peres E, Abidi MH, Mellon-Reppen S, et al. Reduced intensity transplantation for metastatic renal cell cancer with 2-year followup. J Immunother 2007; 30(5): 562-566.
60. Takami A, Takamatsu H, Yamazaki H, et al. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect. Bone Marrow Transplant 2006; 38(11): 729-732.
61. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 2003; 3(7): 526-532.
62. Ayello J, van de Ven C, Cairo E, et al. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol 2009; 37(10): 1216-1229.
63. Bregni M, Bernardi M, Servida P, et al. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplant 2009; 44(4): 237-242.
64. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008; 118(3): 1099-109. Erratum in: J Clin Invest 2008; 118(4): 1584.
65. Varga Z, de Mulder P, Kruit W, et al. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 2003; 49(2): 74-77.
66. Davis ID, Wiseman GA, Lee FT, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 13.
67. Davis ID, Liu Z, Saunders W, et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 14.
68. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. Urol 2006; 175(1): 57-62.
69. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2010.
70. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425.
71. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27(2): 194-203.
72. Yang JC-Y. Interleukin-2: clinical applications. Renal cell carcinoma. In: Rosenburg SA (ed.). Principles and Practice of the Biologic Therapy of Cancer, third edition, Lippincott, Williams and Wilkins: Philadelphia, 2000, pp. 73-82.
73. Schwartzentruber DJ. Biologic therapy with Interleukin-2: clinical applications. In: VT DeVita Jr, Hellman S, Rosenberg SA, (eds). Biologic Therapy of Cancer, second edition. JB Lippincott, Philadelphia, 1995, pp. 235-249.
74. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271(12): 907-913.
75. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228(3): 307-319.
76. Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000; 18(9): 1954-1959.
77. Sleijfer DT, Janssen RA, Buter J, de Vries EG, Willemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10(7): 1119-1123.
78. Sheng XN, Li JL, Guo J, Zhao XH, Zhu J, Chu DT. Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma. Zhonghua Zhong Liu Za Zhi 2008; 30(2): 129-133.
79. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12(8): 1572-1576.
80. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21(16): 3127-3132.
81. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1): 133-141.
82. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl. 1): S55-S57.
83. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113(2): 293-301.
84. Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008; 113(9): 2457-2463.
85. Majhail NS, Wood L, Elson P, Finke J, Olencki T, Bukowski RM.Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study. Clin Genitourin Cancer 2006; 5(1): 50-56.
86. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21(16): 3133-3140.
87. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98(12): 2566-2575.
88. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28(5): 488-495.
89. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9(2): 802-811.
90. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005; 11(10): 3714-3721.
91. Leppert JT, Pantuck AJ. Significance of gene expression analysis of renal cell carcinoma. Expert Rev Anticancer Ther 2006; 6(2): 293-299.
92. Jaeger E, Waldman F, Roydasgupta R, et al. Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders. J Clin Oncol 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 26(15S): 5043.
93. Atkins MB. Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2based immunotherapy. Med Oncol 2009; 26(Suppl 1): 18-22.
94. Jones J, Otu HH, Grall F, et al. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol 2008; 179(2): 730-736.
95. Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol 2009; 16(5): 465-471.
96. Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) select trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7(2): E7-9.
97. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6(1): 34-55.
98. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 289-296.
99. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353(9146): 14-17.
100. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338(18): 1272-1278.
101. Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17(9): 2859-2867.
102. Takayama T, Kai F, Sugiyama T, Furuse H, Mugiya S, Ozono S.Interferon-based cytokine therapy for advanced renal cell carcinoma. Hinyokika Kiyo 2005; 51(8): 499-502.
103. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345(23): 1655-1659.
104. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R.European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358(9286): 966-970.
105. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-3590.
106. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 2008; 8(9): 1295-307.
107. Eriksen KW, Søndergaard H, Woetmann A, et al. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol Immunol 2009; 46(5): 812-820.
108. Thompson JA, Curti BD, Redman BG, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26(12): 2034-2039.
109. Schmidt H, Brown J, Mouritzen U, et al. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res 2010; 16(21): 5312-5319.
110. Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 2010; 10(5): 807-817.
111. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. EurUrol 2006; 50: 34-43.
112. Frankenberger B, Regn S, Geiger C, et al. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 2005; 23: 166-174.
113. Kubler H, Vieweg J. Vaccines in renal cell carcinoma. Semin Oncol 2006; 33: 614-624.
114. Ernstoff MS, Crocenzi TS, Seigne JD, et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res 2007; 13: 733s-740s.
115. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-1546.
116. Pizza G, De Vinci C, Lo Conte G, et al. Allogeneic gene modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha) 2004; 50: 175-183.
117. Fishman M, Hunter TB, Soliman H, et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plussubcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 2008; 31: 72-80.
118. Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther 2010; 17(7): 465-475.
119. Van Poppel H, Joniau S, Van Gool SW. Vaccine therapy in patients with renal cell carcinoma. Eur Urol 2009; 55(6): 1333-1342.
120. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363(9409): 594-599.
121. May M, Brookman-May S, Hoschke B, et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 2010; 59(5): 687-695.
122. Wood C, Srivastava P, Bukowski R, et al. C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372(9633): 145-154.
123. Sznol M, Powderly JD, Smith DC, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO4538) in patients with advanced refractory malignancies. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2010; 28(15 suppl): 2506.
124. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37(5): 508-516.
125. Rini BI, Stein M, Shannon P, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011; 117(4): 758-767.
126. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14(20): 6674-6682.
127. Adotevi O, Pere H, Ravel P, et al. A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Immunother 2010; 33(9): 991-998.
128. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15(6): 2148-2157.
129. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70(9): 3526-3536.
130. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009 Mar 15;69(6):2506-2513.
131. Horiguchi A, Asano T, Kuroda K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010; 102(11): 1592-1599.